Infliximab
Indication
Ankylosing spondylitis (NICE TA383)
NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Red
Brand:
Inflectra®, Remsima®
Nice TA:
383
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Infliximab is recommended, within its marketing authorisations, as an option for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: